Related Experiment Video

Updated: Jul 23, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
12:40

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System

Published on: December 7, 2012

28.7K

Letter to the Editor: "Prophylactic versus restrictive platelet transfusion strategy in patients with haematological

N Motayar1, T Haigh2, M Tomberlin3

  • 1Department of Critical Care Medicine & Intensive Care and Resuscitation, Integrated Hospital Institute, Cleveland Clinic, Ohio, United States of America; Harvard T.H. Chan School of Public Health, Massachusetts, United States of America.

Journal of Critical Care
|August 1, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Routine Screening Method for Microparticles in Platelet Transfusions09:49

Routine Screening Method for Microparticles in Platelet Transfusions

Published on: January 31, 2018

15.9K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

829

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...